Naproxen Fails to Get FDA Heart Safety Nod

February 12, 2014 3:37 PM

18 0

Members of two FDA advisory committees meeting jointly rejected a change in the label on naproxen to reflect a lower cardiovascular risk compared with other nonsteroidal anti-inflammatory drugs (NSAIDs).

Recent evidence convinced nine of the panelists that naproxen carries a lower risk versus others drugs in the class, but failed to sway 16 others.

Read more

To category page